Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals

Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Deals Medical Device

Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology

Fineline Cube Nov 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...

Policy / Regulatory

9th National Volume-Based Procurement Round Results in 70% Price Reduction for 41 Drugs

Fineline Cube Nov 7, 2023

The results of the 9th round of China’s national volume-based procurement (VBP) program have been...

Company Deals

Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital

Fineline Cube Nov 7, 2023

Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in...

Company Drug

Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial

Fineline Cube Nov 7, 2023

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...

Company

FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results

Fineline Cube Nov 7, 2023

US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...

Company Deals

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

Fineline Cube Nov 7, 2023

GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...

Company Drug

Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy

Fineline Cube Nov 7, 2023

Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...

Company Drug

Clover Biopharmaceuticals Submits Market Filing for Seasonal Influenza Vaccine in Brazil

Fineline Cube Nov 7, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for...

Company Deals

WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares

Fineline Cube Nov 7, 2023

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial

Fineline Cube Nov 7, 2023

Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its...

Company Deals Hospital Medical Device

Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery

Fineline Cube Nov 7, 2023

China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic...

Company

Danone Enters China’s Adult FSMP Market with Local Production of Fortimel

Fineline Cube Nov 7, 2023

France-based food company Danone has revealed its strategic plans to enter the adult foods for...

Company Deals

SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China

Fineline Cube Nov 7, 2023

China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with...

Company Drug

RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002

Fineline Cube Nov 7, 2023

RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...

Company Drug

Enhertu Receives Priority Review Status for HER2-Positive Gastric Cancer Treatment in China

Fineline Cube Nov 7, 2023

The Center for Drug Evaluation (CDE) website has indicated that Enhertu (trastuzumab deruxtecan), a HER2-targeted...

Company Deals

Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA

Fineline Cube Nov 7, 2023

Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with...

Company Deals

Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China

Fineline Cube Nov 7, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a...

Company Medical Device

Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE

Fineline Cube Nov 7, 2023

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group)...

Company Deals

BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal

Fineline Cube Nov 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...

Company Drug

MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries

Fineline Cube Nov 6, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...

Posts pagination

1 … 499 500 501 … 717

Recent updates

  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.